Effect of Hydroxytyrosol on NLR, MLR, and SOD in Hypertensive Pregnant Women

The goal of this clinical trial is to evaluate whether hydroxytyrosol supplementation (10 mg/day for 4 weeks) is effective in improving inflammatory and oxidative stress markers in pregnant women diagnosed with hypertensive disorders of pregnancy (including preeclampsia, chronic hypertension, and gestational hypertension). The main questions it aims to answer are: 1. Does hydroxytyrosol supplementation reduce neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR)? 2. Does hydroxytyrosol supplementation lower systolic and/or diastolic blood pressure? 3. Does hydroxytyrosol supplementation increase superoxide dismutase (SOD) levels? Researchers will compare a group receiving hydroxytyrosol supplementation to a standard care control group to see if hydroxytyrosol produces superior anti-inflammatory and antioxidant effects. Participants will: * Take hydroxytyrosol 10 mg orally once daily for 4 weeks (intervention group) or receive standard antenatal care without hydroxytyrosol (control group). * Undergo laboratory testing (NLR, MLR, SOD) before and after the intervention. * Have their blood pressure monitored regularly throughout the study period.

NCT Number	NCT07074548
Lead Sponsor	Dr Cipto Mangunkusumo General Hospital
Conditions	Hypertension in Pregnancy
Enrollment	42 participants
Start Date	2025-07-10
Primary Completion	2025-08-31 (estimated)
Study Completion	2025-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-02